Bristol Myers Squibb (BMY) EBITDA (2016 - 2026)

Bristol Myers Squibb has reported EBITDA over the past 18 years, most recently at $2.8 billion for Q1 2026.

Quarterly EBITDA rose 24.7% to $2.8 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.3 billion through Mar 2026, up 35.84% year-over-year, with the annual reading at $6.8 billion for FY2025, 178.32% up from the prior year.
EBITDA was $2.8 billion for Q1 2026 at Bristol Myers Squibb, up from $1.1 billion in the prior quarter.
Over five years, EBITDA peaked at $2.8 billion in Q1 2026 and troughed at -$11.8 billion in Q1 2024.
The 5-year median for EBITDA is $1.6 billion (2024), against an average of $884.4 million.
Year-over-year, EBITDA tumbled 640.92% in 2024 and then surged 255.96% in 2025.
A 5-year view of EBITDA shows it stood at $1.6 billion in 2022, then dropped by 5.06% to $1.5 billion in 2023, then plummeted by 79.89% to $302.0 million in 2024, then surged by 255.96% to $1.1 billion in 2025, then surged by 163.44% to $2.8 billion in 2026.
Per Business Quant, the three most recent readings for BMY's EBITDA are $2.8 billion (Q1 2026), $1.1 billion (Q4 2025), and $2.2 billion (Q3 2025).

Peer Comparison